ORCID Profile
0000-0002-0517-9535
Current Organisation
University of Adelaide
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Elsevier BV
Date: 10-2017
DOI: 10.1016/J.AVSG.2017.04.029
Abstract: The natural history of type II endoleaks and linkage to aneurysm rupture is unclear. Likewise, treatment recommendations are controversial. The aim of this study was to examine the incidence, factors associated with type II endoleaks, and outcomes in an Australia cohort of patients who have undergone endovascular aneurysm repair (EVAR). Data from 693 patients who underwent EVAR between 2009 and 2013 at multiple institutions across Australia were studied. Patients who developed (1) type II endoleak and (2) type II endoleak with sac expansion were compared for preoperative demographics, mortality, sac expansion, aneurysm rupture, and intervention rates. A total of 225 patients developed type II endoleak over a mean follow-up of 1.9 years (±1.0 years), out of which 133 spontaneously resolved, 37 were untreated unresolved, and 16 underwent intervention. Type I and III endoleaks occurred in 50 and 19 patients, respectively. Smoking (P = 0.002) and warfarin (P = 0.044) were protective factors for development of type II endoleak, whereas age (P = 0.034), right iliac artery tortuosity (P = 0.031), and right (P = 0.008) and left external iliac diameters (P = 0.028) were risk factors for endoleak. Three patients suffered aneurysm ruptures in the entire cohort. All ruptures occurred in type II endoleak patients, of which two occurred after reintervention and in the absence of sac expansion (>5 mm). Late type II endoleak occurred in 117 patients, out of which 26 had sac expansion. Of those without late type II endoleak, 25 have sac expansion. There was no statistically significant difference in survival between those with and without type II endoleak. Age (P < 0.0001) and smoking (P = 0.001) were significant independent predictive factors for survival in this patient s le. Treatment outcomes were encouraging with most cases involving endoleak resolution (15 of 16 patients) and no sac expansion after intervention (0 of 8 patients with complete follow-up info on sac size). Aneurysm rupture in patients with type II endoleak is uncommon in our series. Type II endoleak with sac expansion does not appear to be associated with aneurysm rupture. In this series, most aneurysm ruptures occurred in the absence of documented sac expansion and after reintervention.
Publisher: Elsevier BV
Date: 04-2016
DOI: 10.1016/J.EJVS.2015.12.019
Abstract: The purpose of this study was to determine the preoperative variables that best predict 1-year survival following elective endovascular aneurysm repair (EVAR), a period of time that would suggest the patient had benefited from the procedure. Most EVAR survival studies focus on early and late survival scant information is available for 1-year survival. Data from two Australian audits of EVAR (1999-2001 and 2009-13) were combined (n = 1,647). Preoperative variables included routine demographic data, clinical health assessments, computed tomography-derived anatomical data, and all-cause mortality. Univariate and multivariate logistic regressions determined which variables best predicted 1-year survival. One-year survival after EVAR was 93.7% (1,544/1,647) and 30-day survival was 98.4% (1,620/1,647). Univariate analyses found that nine preoperative variables were significantly associated with 1-year survival. Five variables were included in the final multivariate model: American Society of Anesthesiologists physical status, aneurysm diameter, creatinine, respiratory assessment, and severity of iliac artery calcification (receiver-operator curve 0.717, R(2) = .117). Predicted 1-year survival ranged from 98.6% to 68.0%, based on differences in aneurysm size and patient comorbidities. Personalised 1-year survival risk enables surgeons and patients to consider seriously the risks and benefits of EVAR prior to surgery.
Location: United Kingdom of Great Britain and Northern Ireland
No related grants have been discovered for Margaret Boult.